Michael Imperiale, MD

A biopharmaceutical executive with over 25 years of experience in global drug development, with an emphasis in rare diseases. Michael’s experience includes leading the clinical development and successful NDA approval for Chenodal for Cerebrotendinous Xanthomatosis (CTX), and Viramune for HIV. He has also headed multiple studies in Mucopolysaccharidoses (MPS) and Phenylketonuria (PKU), and developed programs for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) and Spinal Bulbar Muscular Atrophy (SBMA). Currently, at Actio Biosciences, Michael is the program lead for ABS-0871, a novel TRPV4 inhibitor for the treatment of Charcot Marie Tooth Disease Type 2C (CMT-2C). ABS-0871 has received FDA Fast Track designation, and is currently in phase 1a of development.